C90.01

Clinical Causes: Genetic mutations leading to abnormal plasma cell growth Environmental exposures such as radiation or certain chemicals Advanced age, as the disease is more common in older adults History of precursor conditions like monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma Family history of plasma cell disorders Weakened immune system or certain immune conditions

Key Symptoms: Bone pain, especially in the back, ribs, or skull Fatigue and weakness due to anemia Frequent infections owing to immune system impairment Increased thirst and urination caused by high calcium levels Unexplained weight loss Broken bones or fractures with minimal trauma Numbness or weakness in limbs from nerve compression Swelling or fractures in bones

Diagnosis Path: Diagnosis of multiple myeloma involves a combination of clinical assessments, laboratory testing, imaging studies, and bone marrow examination. Key diagnostic steps include: - Blood tests: To detect abnormal monoclonal proteins (M-proteins), evaluate blood cell counts, kidney function, and calcium levels. - Urine tests: To identify Bence Jones proteins, a type of light chain protein excreted in urine. - Bone marrow biopsy: To examine plasma cell percentage and morphology. - Imaging studies: Such as X-rays, MRI, or PET scans to identify bone lesions or fractures. When diagnosed and successfully treated, some patients achieve remission, reflected in the ICD-10 code C90.01. In remission, disease activity is reduced or absent, but ongoing monitoring continues to check for potential recurrence.

Treatment Protocols: Treatments for multiple myeloma aim to control the disease, prevent complications, and improve quality of life. In remission, management strategies include: - Observation: Regular follow-up and monitoring without active treatment - Maintenance therapy: To prolong remission periods, such as low-dose chemotherapy, immunomodulatory drugs, or targeted therapies - Supportive care: Includes bisphosphonates for bone health, blood transfusions for anemia, and dialysis if kidney function is affected - Clinical trials: Participation in research studies for emerging treatments It is essential for patients in remission to continue regular medical evaluations to detect any signs of relapse early. Managing side effects and maintaining overall health are also vital components of ongoing care.